Ligand Pharmaceuticals (LGND) To Acquire Metabasis Therapeutics (MBRX)
More News related to LGND
- Ligand Pharma (LGND) Reports Data on SARM
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
- Ligand Pharma (LGND) Receives $2M in Milestone Payments from N.V. Organon
- Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
More News related to MBRX
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Ligand Pharmaceuticals (LGND) To Acquire Metabasis Therapeutics (MBRX)
- Metabasis Announces Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Morning Movers 10/09: SCIL, MBRX, CAGC, AVNR, PSTA, SRZ, ELGX Higher; SPPI, ACOR, LXRX Lower
More News related to Mergers and Acquisitions
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Metabasis Therapeutics, Inc. (NASDAQ: MBRX) entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis.
Under the transaction, Metabasis stockholders will receive a cash payment at the closing of the transaction of approximately $3.2 million, less Metabasis' estimated net liabilities at closing and an amount to be deposited in the stockholders' representative’s fund (Metabasis currently estimates the closing payment to be approximately $1.8 million in cash). In addition, Metabasis stockholders will receive for each Metabasis share four tradable Contingent Value Rights (CVRs) that will be registered on a Form S-4 registration statement to be filed by Ligand with the Securities and Exchange Commission. The CVRs will entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by Ligand from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. Ligand has committed to spend at least $8 million in new research and development funding on the Metabasis programs within 42 months following the closing of the transaction.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.09
-0.02Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Class action
Kim on Oct 28, 2009 11:52 AMHow can a company make a deal to sell that takes its stock from $.91 to $ .41 overnight. Is that representing it's stockholders? How long do you think it will be till the class action suits start?